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In Salmonella enterica serovar Typhimurium, the Cra protein (catabolite repressor/activator) regulates
utilization of gluconeogenic carbon sources by activating transcription of genes in the gluconeogenic pathway,
the glyoxylate bypass, the tricarboxylic acid (TCA) cycle, and electron transport and repressing genes encoding
glycolytic enzymes. A serovar Typhimurium SR-11 cramutant was recently reported to be avirulent in BALB/c
mice via the peroral route, suggesting that gluconeogenesis may be required for virulence. In the present study,
specific SR-11 genes in the gluconeogenic pathway were deleted (fbp, glpX, ppsA, and pckA), and the mutants
were tested for virulence in BALB/c mice. The data show that SR-11 does not require gluconeogenesis to retain
full virulence and suggest that as yet unidentified sugars are utilized by SR-11 for growth during infection of
BALB/c mice. The data also suggest that the TCA cycle operates as a full cycle, i.e., a sucCD mutant, which
prevents the conversion of succinyl coenzyme A to succinate, and an sdhCDA mutant, which blocks the
conversion of succinate to fumarate, were both attenuated, whereas both an SR-11 aspAmutant and an SR-11
frdABC mutant, deficient in the ability to run the reductive branch of the TCA cycle, were fully virulent.
Moreover, although it appears that SR-11 replenishes TCA cycle intermediates from substrates present in
mouse tissues, fatty acid degradation and the glyoxylate bypass are not required, since an SR-11 fadDmutant
and an SR-11 aceA mutant were both fully virulent.
In sensitive mice, Salmonella enterica serovar Typhimurium
causes a systemic, often fatal disease, similar to human typhoid
fever (43). After ingestion, serovar Typhimurium survives pas-
sage through the acidic environment of the stomach and
reaches the terminal ileum where, within 30 min, it invades M
cells in the Peyer’s patches (22). Within 60 min, the M cells are
destroyed and serovar Typhimurium gains access to both ad-
jacent enterocytes and to underlying lymphoid cells in the
mesenteric lymph follicles of the Peyer’s patches (22, 24). Se-
rovar Typhimurium grows logarithmically in Peyer’s patches
for 2 days (20) and simultaneously disseminates systemically to
the liver and spleen, where it grows in macrophages (40, 43).
Mice usually become ruffled and lethargic 3 to 5 days post-oral
infection and usually die within 7 to 12 days. Despite much
work relating to the relevant virulence mechanisms, little is
known about the nutrition of serovar Typhimurium during
infection.
The Cra protein (catabolite repressor/activator) is a regula-
tor of central carbon metabolism in salmonellae and Esche-
richia coli. Cra is a transcription factor that activates genes
encoding key enzymes in the glyoxylate bypass, gluconeogen-
esis, the tricarboxylic acid (TCA) cycle, and electron transport
and represses genes encoding key enzymes in the Embden-
Meyerhof and Entner-Doudoroff pathways (42). It has recently
been reported that a cra mutant of serovar Typhimurium
SR-11 is totally avirulent and immunogenic in BALB/c mice
when administered orally but remains fully virulent when ad-
ministered intraperitoneally (1, 48). These findings suggested
the possibility that while crossing the intestine, the ability to
utilize gluconeogenic substrates may be required for serovar
Typhimurium SR-11 virulence. In support of this view, Valen-
tine and coworkers (49) reported that a MudJ insertion in a
serovar Typhimurium NAD-linked malate oxidoreductase ren-
dered it avirulent via the oral route in BALB/c mice. In the
present study, the roles of gluconeogenesis and the TCA cycle
in the virulence of serovar Typhimurium strain SR-11 were
investigated systematically.
MATERIALS AND METHODS
Bacterial strains, plasmids, and growth media. Bacterial strains and plasmids
used in this study are listed in Table 1. Luria Bertani (LB) broth (Fischer
Biotech, Fair Lawn, New Jersey), LB agar, Lennox (Difco Laboratories, Detroit,
Michigan), and MacConkey agar (Difco) were prepared according to package
instructions. Liquid M9 minimal salts medium (31) was supplemented either with
reagent grade glucose (0.2% wt/vol), glycerol (0.2% wt/vol), malic acid (0.4%
wt/vol), sodium citrate (0.4% wt/vol), and sodium oleate (5 mM) plus 5 mg of Brij
58/ml, sodium pyruvate (0.4% wt/vol), sodium succinate (0.4% wt/vol), or potas-
sium acetate (0.4% wt/vol) as sole sources of carbon and energy. When neces-
sary, the pH was adjusted to 7.2. SOC medium was prepared as described by
Datsenko and Wanner (9). Bacterial strains were grown for 24 h at 37°C in liquid
culture media or overnight on LB agar plates. Liquid cultures were supple-
mented with nalidixic acid (50 g/ml), and agar plates were supplemented with
nalidixic acid (50 g/ml), chloramphenicol (30 g/ml), ampicillin (100 g/ml), or
kanamycin (40 g/ml) where appropriate.
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Construction and characterization of serovar Typhimurium SR-11 deletion
mutants. Mutant strains of SR-11 were created by deletion mutagenesis using
either a chloramphenicol cassette or a kanamycin cassette as described by Dat-
senko and Wanner (9). All constructs were verified by PCR and sequencing. The
specific primers used to construct the deletions and to confirm the allelic ex-
change were designed for each of the mutants by referring to the complete
genome of Salmonella enterica serovar Typhimurium LT2 (28) and are listed in
Table 2. In instances where the chloramphenicol cassette or the kanamycin
cassette might cause downstream polar effects, the cassettes were removed as
described by Datsenko and Wanner (9). For sequencing, PCR products were
TABLE 1. Strains of serovar Typhimurium and plasmids used in this study
Strain or plasmid Genotypea and defect(s) or relevant characteristics Source or reference
SR-11 strains
Wild type gyr1816; none 8
Fad AX-2 gyr1816 cra::Tn10 d cam; Cra repressor/activator protein 1
glpX gyr1816 glpX::cat; glpX-encoded fructose-1,6-bisphosphatase This study
fbp gyr1816 fbp::cat; fbp-encoded fructose-1,6-bisphosphatase This study
glpX fbp gyr1816 glpX fbp::cat; glpX-and fbp-encoded fructose-1,6-bisphosphatases This study
pckA gyr1816 pckA::cat; PEP carboxykinase This study
ppsA gyr1816 ppsA::cat; PEP synthase This study
ppsA pckA gyr1816 ppsA pckA::cat; PEP caboxykinase, PEP synthase This study
acs gyr1816 acs; acetate synthase This study
fadD gyr1816 fadD::cat; acyl-CoA synthase This study
aspA gyr1816 aspA; aspartase This study
sfcA gyr1816 sfcA::kan; malate oxidoreductase (NAD dependent) This study
maeB gyr1816 maeB::kan; malate oxidoreductase (NADP dependent) This study
sfcA maeB gyr1816 maeB sfcA::kan; both malate oxidoreductases This study
aceA gyr1816 aceA; isocitrate lyase This study
ppc gyr1816 ppc; PEP carboxylase This study
sucAB gyr1816 sucAB; -ketoglutarate dehydrogenase This study
sucCD gyr1816 sucCD; succinyl-CoA synthetase This study
sdhCDA gyr1816 sdhCDA; succinate dehydrogenase This study
frdABCD gyr1816 frdABCD; fumarate reductase This study
mdh gyr1816 mdh; malate dehydrogenase This study
kgtP gyr1816 kgtP; -ketoglutarate transporter This study
dctA gyr1816 dctA; dicarboxylate transporter This study
kgtP dctA gyr1816 kgtP dctA; dicarboxylate transporter, -ketoglutarate transporter This study
Plasmids
pKD3 Template plasmid, contains chloramphenicol resistance cassette flanked by FLP recombinase
target sites; bla cat
9
pKD4 Template plasmid, contains kanamycin resistance cassette flanked by FLP recombinase
target sites; bla kan
9
pKD46 Temperature-sensitive plasmid, contains arabinose-inducible phage  red recombinase gene
for linear DNA exchange; bla
9
pCP20 Temperature-sensitive plasmid, contains FLP recombinase gene for removal of antibiotic
resistance cassettes; bla cat
9
a All mutants were constructed using either the chloramphenicol (cat) or kanamycin (kan) resistance cassette as described by Datsenko and Wanner (9). The
resistance cassettes were removed from the deletion mutants lacking the ::cat or ::kan designation, as described by Datsenko and Wanner (9).
TABLE 2. Sequences of primers used to confirm serovar Typhimurium mutants
Gene Forward primer sequence (5–3) Reverse primer sequence (5–3)
glpX CGTATCATGCTCAACCAG TCCGGATCTTTACGATCA
fbp TACGGTTATTGGTAGGGAGAGC GTTGTGCATGTTATGTTCGCCG
pckA CGTAAATCTATGAGCCTTGTCG TGGCACCAGCGAGCGTGGCG
ppsA CAGGGAATGCCGTGCTATGC TGACGCTGGAAGAGGTGATC
Acs ATTGCGGATCGTTGCCTG ACGCCAGGATCGGCGAGA
fadD GCTGATGTTCCGGCGGAG CACGGGCTTCGTCACGCA
aspA TCCAGCTGAAGCCTACTA CCAGCACAACTTCACGTA
sfcA TCAGTGATGAATATTAAACCAACAGG TGCACAATTTTAGCCGCATCTTCCG
maeB CCGGTTAGCGCGAGGATTTGC CACCGACTATTCTTTGTATTACTACC
aceA GTACTCAACAAATCGAAG ACGCGGTAACGGATGACG
ppc CATCAACGCCTGTTCGAC ATGACGAGCTGCTGCCAG
sucAB TGGACAGACTGGACGAAC TGTGCTGCAGGTTCAACA
sucCD GTACTACTCCGCGTGAAG AGGTGGCCAACCATGTCG
sdhCDA CAGGTAGATTCACCTCTG GTGAGCGTTGGTGGTGGA
frdABCD ACGGTGACTACCGCAGTG GCTGCGTGATATGGAATTCGT
mdh CGATAAGACGTGAGGAGT CAGCCGATCCGGATTACG
kgtP CGACAGCGCGACATATTC GAGATGCGGCGACGCATA
dctA CTGACAGCAATCGCCATT TAAGCACATCGTCCAGCT
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purified with a QIAGEN Qiaquick PCR purification kit (QIAGEN, Maryland)
following the manufacturer’s instructions. Each sequencing mixture contained
between 50 and 150 ng of PCR product, 1.6 pmol of primer, and 8.0 l of dye
terminator cycle sequencing quick start master mix (Beckman Coulter, Fullerton,
California). The thermal cycling program contained 30 cycles of denaturation at
96°C for 20 s, annealing at 50°C for 20 s, and elongation at 60°C for 4 min. After
completion of the cycle sequencing, samples were purified by ethanol precipita-
tion and separated by polyacrylamide gel electrophoresis on a CEQ 8000 genetic
analysis system (Beckman Coulter).
Growth of mutants on various carbon sources. Wild-type serovar Typhi-
murium SR-11 and its deletion mutants were grown overnight in LB at 37°C with
shaking to about 109 CFU/ml. Cultures were washed twice with M9 minimal salts
medium (31) lacking a carbon source and were resuspended in the same medium
at about 109 CFU/ml. The washed cultures were diluted to about 105 CFU/ml in
M9 minimal salts medium supplemented with one of the carbon sources listed
above. Cultures were grown for 24 h at 37°C with shaking. Growth was assessed
visually by the presence or absence of turbidity.
The generation times of selected attenuated and nonattenuated mutants in M9
minimal salts medium containing reagent grade glucose (0.2% wt/vol) were
determined. Inocula were prepared as follows. Overnight cultures (10 ml) in LB
were started from single colonies on Luria agar plates and were incubated at
37°C with shaking in 125-ml tissue culture bottles. The next morning, the LB
cultures were washed twice in M9 minimal medium (no carbon source), and 10
l of the washed cultures was transferred to M9 minimal glucose (0.2% wt/vol)
medium and then incubated overnight at 37°C with shaking in 125-ml tissue
culture bottles. The next morning, each culture was diluted to an A600 reading of
about 0.08 into fresh M9 medium (10 ml) containing glucose (0.2% wt/vol) and
supplements, as required (see text). The cultures were incubated at 37°C with
shaking in 125-ml tissue culture bottles. Growth was monitored spectrophoto-
metrically (A600) using a Pharmacia Biotech Ultrospec 2000 UV/visible spectro-
photometer. Generation times were determined from three independent exper-
iments with each strain from semilogarithmic plots of the growth data (log10 A600
versus time).
Virulence assays. Virulence assays were carried out as described previously
(1). Four-week-old, 13- to 15-g female BALB/c mice (Charles River Laborato-
ries, Wilmington, MA) were housed no more than 4 per cage, with pine shavings
as bedding. Prior to infection, the mice were starved for food and water for 4 h.
Following starvation, 50 l of 10% sodium bicarbonate was administered orally
to each mouse to neutralize gastric acidity, and 30 min later, 108 CFU of a
specific strain in 20 l of phosphate-buffered saline (pH 7.4) containing 0.1%
gelatin was administered orally to each of 4 mice. For virulence assays via the
intraperitoneal route, 103 CFU of a specific strain in 100 l of phosphate-
buffered saline (pH 7.4) containing 0.1% gelatin were injected by sterile syringe
into each of 4 mice. The number of CFU administered to mice was measured by
diluting and then plating bacterial suspensions onto MacConkey agar containing
nalidixic acid (50 g/ml). After infection, food and water were returned and the
mice were inspected four times daily for signs of illness and death. The virulence
data presented here for each strain are a composite of the results from at least
two independent experiments in which 4 mice were infected with a specific
mutant and 4 additional mice were infected with the SR-11 wild-type strain.
Where noted in the figures, data from a composite of three independent exper-
iments are presented.
Statistics. Mouse survival curves were compared for differences using the
Kaplan-Meier method (MedCalc Software, Belgium). Survival curves were con-
sidered to be different if the P value was less than 0.05. Where indicated in the
text, the generations times derived from triplicate samples of specific SR-11
mutants were compared to the generation time derived from triplicate samples
of the SR-11 wild-type by Student’s t test. Generation times were considered to
be different if the P value was less than 0.05.
RESULTS
Definition of fully virulent, attenuated, and avirulent (108
CFU/mouse, peroral route). In addition to infecting 4 mice
orally with 108 CFU of the wild-type SR-11 in each virulence
experiment, 4 mice were infected orally with 108 CFU of the
SR-11 cra mutant (Table 1). All of the mice infected with the
SR-11 cra mutant in all experiments remained healthy
throughout the duration of the experiment, which is our defi-
nition of avirulent. The term fully virulent is used when the
survival curve of mice infected with a particular mutant is not
statistically different from that of mice infected with the wild-
type SR-11 strain. The term attenuated is used when the sur-
vival curve of mice infected with a particular mutant is statis-
tically different from that of mice infected with the wild-type
SR-11 strain and death is delayed. The extent to which death is
delayed is denoted by the terms slightly attenuated, attenuated,
or highly attenuated, which will become clear after viewing the
figures.
Gluconeogenesis is not required for full SR-11 virulence
(108 CFU/mouse, peroral route). During gluconeogenesis, the
conversion of fructose-1,6-bisphosphate to fructose-6-phos-
phate is catalyzed irreversibly by fructose-1,6-bisphosphatase,
encoded by fbp (44). An fbp mutant is therefore unable to carry
out gluconeogenesis above fructose-1,6-bisphosphate but is
able to carry out glycolytic reactions normally (Fig. 1). A sec-
ond fructose-1,6-bisphosphatase has been characterized in E.
coli, encoded by glpX (11); however, GlpX has been shown to
be functional only when overexpressed (11). A glpX homolog is
present in serovar Typhimurium (28). An SR-11 fbp mutant,
an SR-11 glpX mutant, and an SR-11 glpX fbp double
mutant were constructed. As expected, the SR-11 fbp mutant
and the SR-11 glpX fbp double mutant grew with glucose as
the sole carbon source but, in contrast to wild-type SR-11,
FIG. 1. Embden Meyerhoff pathway, gluconeogenic pathway, and
TCA cycle. Arrows indicate the physiological directions of the reac-
tions. Genes encoding the enzymes for each reaction are listed beside
each reaction.
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failed to grow on glycerol and gluconeogenic substrates (ace-
tate, citrate, malate, succinate, oleate, and pyruvate) as sole
carbon and energy sources (not shown). However, the SR-11
glpX mutant (P  0.98), the SR-11 fbp mutant (P  0.35),
and the SR-11 glpX fbp double mutant (P 0.50) were each
as virulent as the wild-type SR-11 (Table 3), suggesting that as
yet unidentified sugars that feed into the glycolytic/gluconeo-
genic pathway at or above fructose-6-phosphate are utilized for
growth during infection.
Although the SR-11 glpX fbp double mutant cannot com-
plete gluconeogenesis above fructose-1,6-bisphosphate, it can
still make all the intermediates from pyruvate to fructose-1,6-
bisphosphate from gluconeogenic substrates (Fig. 1). Glucone-
ogenesis can be prevented above pyruvate by blocking the
production of phosphoenolpyruvate (PEP) from both oxaloa-
cetate via phosphoenolpyruvate carboxykinase, encoded by the
pckA gene (29), and from pyruvate via phosphoenolpyruvate
synthase, encoded by the ppsA gene (33) (Fig. 1). An SR-11
ppsA mutant, an SR-11 pckA mutant, and an SR-11 ppsA
pckA double mutant were constructed. As expected, the
SR-11 ppsA pckA double mutant grew with glucose as the
sole carbon and energy source (Table 4) but was unable to
utilize gluconeogenic substrates for growth (not shown). The
SR-11 ppsA mutant (P  0.84) and the SR-11 pckA mutant
(P  0.14) were fully virulent (Table 3); however, the SR-11
ppsA pckA mutant (P  0.02) was found to be slightly
attenuated, i.e., death was delayed by about 2 days (Fig. 2).
Since the SR-11 glpX fbp double mutant is fully virulent and
the SR-11 ppsA pckA double mutant appears to be only
slightly attenuated, gluconeogenesis plays, at most, a minor
role in SR-11 virulence, i.e., the avirulence of the SR-11 cra
mutant can’t be explained by its inability to perform glucone-
FIG. 2. Survival of BALB/c mice infected orally with 108 CFU of
either wild-type SR-11 (■) or the SR-11 ppsA pckA double mutant
(E).
TABLE 3. Virulence of SR-11 mutants: oral infection (108/mouse)
Pathway and
mutant strain
Day 50%
mortality
reached for:
Day 100%
mortality
reached for:
Kaplan-
Meier
P valuea
Wild type Mutant Wild type Mutant
Gluconeogenesis
fbp 6.5 5.5 9 8 0.35
glpX 6.5 6 9 10 0.98
fbp glpX 7 8 9 16 0.50
pckA 7 8 11 11 0.14
ppsA 8.5 8 12 13 0.84
pckA ppsA 8 10 11 18 0.02
Malate to pyruvate
maeB 7.5 6 13 9 0.079
sfcA 7.5 8 13 12 0.77
sfcA maeB 6.5 11 9 19 0.0001
TCA cycle
sucAB 9 	32 10 	32 0.0001
sucCD 8 18 14 	32 0.0068
sdhCDA 8 11 14 	22 0.15
sdhCDA
(106 CFU)
9 13 14 	22 0.0051
sdhCDA
composite
(16 mice)
8.5 12 14 	22 0.0026
mdh (12 mice) 7.5 20 14 	34 <0.0001
TCA cycle
(reductive
branch)
aspA 7 8 11 12 0.20
frdABCD 8 7 14 15 0.98
Acetate, fatty acids,
glyoxylate
bypass
aceA 8 8 9 11 0.49
acs 8 8 9 17 0.69
fadD 8 9 9 11 0.65
Anapleurotic
ppc 7.5 7.5 14 12 0.93
dctA 7.5 7.5 13 11 0.71
kgtP 5.5 6.5 13 9 0.26
dctA kgtP 6.5 8.5 13 9 0.98
a P values denoting statistical differences between the survival curves of mice
infected with the SR-11 wild type and a specific mutant are shown in boldface type.
TABLE 4. Generation times of serovar Typhimurium SR-11 mutants growing aerobically in M9 minimal medium containing
glucose (0.2% wt/vol)
Growth medium
Generation time (min) 
 SD (n  3) for:
Wild type mdh sdhCDA sucCD ppsA pckA sfcA maeB sucAB ppc
M9Ga 79 
 4 95 
 5 81 
 4 80 
 6 79 
 6 84 
 5 NGd NG
M9GAKb 64 
 2 NDe ND ND ND ND ND 92 
 2
M9GDLMc 69 
 2 ND ND ND ND ND 72 
 4 ND
a M9G, M9 minimal medium containing glucose (0.2% wt/vol).
b M9GAK, M9G supplemented with 0.01% aspartate and 0.01% -kletoglutarate.
c M9GDLM, M9G containing diaminopimelate (40 g/ml), lysine (50 g/ml), and methionine (50 g/ml).
d NG, no growth.
e ND, not done.
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ogenesis. Moreover, since the SR-11 ppsA pckA double
mutant is unable to make any gluconeogenic intermediates
above pyruvate, it appears that the majority of metabolic in-
termediates from fructose-1,6-bisphosphate to PEP required
for full virulence can be produced glycolytically.
Phosphoenolpyruvate carboxylase is not required for full
SR-11 virulence (108 CFU/mouse, peroral route). Phos-
phoenolpyruvate carboxylase (Ppc), which converts PEP to
oxaloacetate (41), replenishes the TCA cycle when precursor
metabolites are withdrawn for biosynthesis under conditions
where a high level of sugar is available as the sole carbon and
energy source (47). Since SR-11 appeared to obtain the ma-
jority of its PEP glycolytically in vivo, it was of interest to
examine the role of Ppc in SR-11 virulence. An SR-11ppc
mutant was constructed and, as reported previously for serovar
Typhimurium (47), was unable to grow using either glucose or
glycerol as a sole carbon source unless cofactor amounts
(0.01%) of both aspartate and -ketoglutarate were added to
the medium. Therefore, the SR-11 ppc mutant does not ap-
pear to utilize the glyoxylate bypass as an alternative anapleu-
rotic pathway for replenishment of oxoloacetate, as has been
reported for a ppc mutant of E. coli strain BW25113 (37). As
expected, the SR-11 ppc mutant grew normally on either
acetate or citrate as a sole carbon source (not shown). Despite
its growth defect on sugars, the SR-11 ppc mutant (P  0.93)
was fully virulent (Fig. 3), suggesting that anapleurotic forma-
tion of oxaloacetate from PEP is not required during SR-11
infection.
The reductive branch of the TCA cycle is not required for
full SR-11 virulence (108 CFU/mouse, peroral route). During
anaerobic growth in the absence of an alternative electron
acceptor, the TCA cycle does not function as a full cycle but as
an oxidative branch which runs from citrate to -ketoglutarate
and a reductive branch which runs backwards from oxaloac-
etate to succinyl coenzyme A (succinyl-CoA) (Fig. 1) (7, 39).
Under these conditions, both branches serve biosynthetic func-
tions and are not used for energy generation (7). The reductive
branch runs in part via reversal of the direction of the TCA
cycle using the enzymes of the TCA cycle and in part via
aspartate aminotransferase, encoded by aspC (14), which gen-
erates aspartate from oxaloacetate and via aspartase, encoded
by aspA (46), which generates fumarate from aspartate (7).
Succinate is then generated from fumarate via fumarate reduc-
tase (7), encoded by the frdABCD genes (6), and succinyl-CoA
is generated from succinate via succinyl-CoA synthetase (7),
encoded by the sucCD genes (3). Succinyl-CoA is derived from
succinate via succinyl-CoA synthetase rather than from -ke-
toglutarate via -ketoglutarate dehydrogenase (sucAB) be-
cause anaerobically -ketoglutarate dehydrogenase synthesis is
severely repressed relative to other TCA cycle enzymes (7, 35).
Succinate dehydrogenase (sdhCDAB) is also severely re-
pressed under anaerobic conditions in the absence of an alter-
native electron acceptor (21, 36).
To determine whether SR-11 virulence depends on the re-
ductive branch of the TCA cycle, an SR-11 aspA mutant and
an SR-11 frdABCD mutant were constructed and tested for
virulence. Both the SR-11 aspA mutant (P  0.20) and the
SR-11 frdABCD mutant (P  0.98) were fully virulent (Table
3), suggesting that the TCA cycle does not function in the
branched mode during SR-11 infection. Furthermore, these
data suggest that extracellular aspartate is not being used to
replenish fumarate in the TCA cycle during SR-11 infection.
Role of the TCA cycle in SR-11 virulence (108 CFU/mouse,
peroral route). Since it appeared that the branched operation
of the TCA cycle was not required for full SR-11 virulence, it
seemed that a complete TCA cycle might be necessary. There-
fore, several TCA cycle mutants were constructed, and as de-
scribed below, growth phenotypes were as in previously pub-
lished reports (7, 18, 50). With the exception of the SR-11
sucAB mutant, all the TCA cycle mutants grew with glucose
as a sole carbon and energy source (Table 4). The SR-11
sucAB mutant, unable to convert -ketoglutarate to succinyl-
CoA (Fig. 1) and therefore unable to grow on either acetate or
citrate as a sole carbon and energy source (not shown), was
totally avirulent (P  0.0001) (Fig. 4A). In addition, the SR-11
sucCD mutant, unable to convert succinyl-CoA to succinate
and therefore unable to grow on citrate or acetate as a sole
carbon source (not shown), was attenuated (P  0.0068) (Fig.
4B). Furthermore, the SR-11 mdh mutant, unable to convert
malate to oxaloacetate via malate dehydrogenase (51) and
therefore unable to grow on either citrate or malate as a sole
carbon and energy source (not shown), was highly attenuated
(P 0.0001) (Fig. 4C). The SR-11 sdhCDA mutant, unable to
convert succinate to fumarate and therefore unable to grow on
acetate or succinate as a sole carbon and energy source (not
shown), was fully virulent statistically (P  0.15) but appeared
attenuated visually (Fig. 4D). Therefore, the SR-11 sdhCDA
mutant was tested for virulence at a 100-fold-lower level (106
CFU/mouse) and was found to be attenuated (P  0.0051)
(Table 3). Moreover, comparison of the SR-11 wild-type sur-
vival curve and the SR-11 sdhCDA mutant survival curve
generated from the combined data of the 108 CFU and 106
CFU virulence assays (16 mice) (Fig. 4E) also showed that the
SR-11 sdhCDA mutant was attenuated (P  0.0026). Since
expression of all the TCA cycle genes tested are necessary for
full virulence, it appears that the complete TCA cycle runs
during SR-11 infection and is necessary for full virulence.
Role of malate oxidoreductase in SR-11 virulence (108 CFU/
mouse, peroral route). Pyruvate can be generated from PEP by
the PEP-dependent, sugar-transporting phosphotransferase
system (PTS), from PEP via pyruvate kinase glycolytically, or
FIG. 3. Survival of BALB/c mice infected orally with 108 CFU of
either wild-type SR-11 (■) or the SR-11 ppc mutant (E).
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from malate via malate oxidoreductase (“malic enzyme”) (Fig.
1). Serovar Typhimurium contains an NAD-dependent malate
oxidoreductase, encoded by the sfcA gene (26) and an NADP-
dependent malate oxidoreductase, putatively encoded by the
maeB gene (2). It has been reported that a MudJ insertion in
the sfcA gene rendered serovar Typhimurium avirulent after
oral infection in BALB/c mice (49). We were unable to confirm
that an SR-11 sfcA mutant was avirulent. In fact, in our
hands, both the SR-11 sfcA mutant (P  0.77) and the SR-11
maeB mutant (P  0.079) were fully virulent (Table 3). How-
ever, although not avirulent, the SR-11 sfcA maeB double
mutant was attenuated (P  0.0001) (Fig. 5). These data sug-
gest that a major source of pyruvate during SR-11 infection is
from malate. Moreover, since it appears that pyruvate gener-
ated from malate during SR-11 infection is not used to any
great extent for gluconeogenesis, it is likely that it is used, at
least in part, to generate acetyl-CoA, which, in addition to
being necessary for citrate formation for the TCA cycle, is the
precursor of fatty acids for phospholipid biosynthesis.
The glyoxylate bypass is not required for full SR-11 patho-
genesis (108 CFU/mouse, per-oral route). The glyoxylate by-
pass (Fig. 1), required for utilization of two major gluconeo-
genic carbon sources, acetate and fatty acids (7), has been
reported to not be required for serovar Typhimurium strain
FIG. 4. Survival of BALB/c mice infected orally with 108 CFU of either wild-type SR-11 (■) or the SR-11 sucAB mutant (E) (A), 108 CFU
of either wild-type SR-11 (■) or the SR-11 sucCD mutant (E) (B), 108 CFU of either wild-type SR-11 (■) or the SR-11 mdh mutant (E) (C),
or 108 CFU of either wild-type SR-11 (■) or the SR-11 sdhCDA mutant (E) (D). (E) Composite of mice infected with 108 CFU and 106 CFU
of either wild-type SR-11 (■) or the SR-11 sdhCDA mutant (E).
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14028s acute virulence (13). To determine whether the glyoxy-
late bypass contributes to SR-11 virulence, an SR-11 aceA
mutant was constructed which is unable to convert isocitrate to
glyoxylate and succinate (Fig. 1) (27). As expected, the SR-11
aceA mutant was unable to utilize either acetate or oleate as
a sole source of carbon and energy (not shown) and, in agree-
ment with Fang et al. (13), was found to be fully virulent (P 
0.49) (Table 3). Therefore, the glyoxylate bypass is not re-
quired for SR-11 virulence. Furthermore, an SR-11 fadD
mutant (P 0.65), unable to degrade fatty acids to acetyl-CoA
(Fig. 1), and an SR-11 acs mutant (P  0.69), unable to
convert acetate to acetyl-CoA (Fig. 1), were unable to grow
with oleate and acetate as a sole carbon and energy source,
respectively (not shown), but were fully virulent (Table 3).
These data suggest that neither external acetate nor fatty acids
present in mouse tissues are required as sources of acetyl-CoA
for running the TCA cycle during SR-11 infection.
Growth of attenuated mutants aerobically in glucose mini-
mal medium. The evidence to this point suggested that cyclic
operation of the TCA cycle is required for full SR-11 virulence
in BALB/c mice. However, it might be argued that the atten-
uated TCA cycle mutants have general growth defects that
would be observed even if the TCA cycle were not running as
a full cycle. It was therefore of interest to examine growth rates
of the attenuated SR-11 TCA cycle mutants during aerobic
growth with glucose (0.2% wt/vol) as the sole source of carbon
and energy (Table 4), a condition in which the TCA cycle
operates in the oxidative and reductive branched mode (7, 32),
requiring neither succinate dehydrogenase nor -ketoglutarate
dehydrogenase (5, 7). Under these conditions, the generation
time of the attenuated SR-11 mdh mutant (Table 4) was
significantly greater than that of the wild-type SR-11 strain (P
 0.02), suggesting that malate dehydrogenase is indeed nec-
essary for running the reductive branch of the TCA cycle as
well as the full TCA cycle. Therefore, malate dehydrogenase
would most likely be required for full virulence whether or not
the TCA cycle was running as a full cycle in vivo. In contrast,
the generation times of the attenuated SR-11 sdhCDA mu-
tant (Table 4) and the attenuated SR-11 sucCD mutant (Ta-
ble 4) were essentially the same as that of the wild-type SR-11
(P 	 0.10 in each case), suggesting that the attenuation ob-
served in vivo is in fact due to the inability of these mutants to
run a full TCA cycle.
The remaining attenuated SR-11 mutants were also grown
on glucose aerobically, and generation times were determined.
The generation times of the slightly attenuated SR-11 ppsA
pckA double mutant and the generation time of the attenu-
ated SR-11 sfcA maeB double mutant were the same as that
of the SR-11 wild-type strain (P	 0.10 in each case) (Table 4).
These data suggest that when growing on glucose aerobically,
i.e., under conditions in which gluoneogenesis driven by TCA
cycle intermediates is not necessary, these mutants can achieve
maximum SR-11 growth rates. It therefore appears that atten-
uation of the SR-11 ppsA pckA and SR-11 sfcA maeB
mutants in BALB/c mice is due to defects in their inability to
send TCA cycle intermediates out of the TCA cycle under in
vivo conditions and not due to nonspecific growth defects.
The avirulent SR-11 sucAB mutant does not grow on glu-
cose aerobically unless diaminopimelic acid, lysine, and methi-
onine are added to the growth medium (5). With these sup-
plements, however, the SR-11 sucAB mutant and the SR-11
wild-type strain grew with identical generation times (P	 0.10)
(Table 4). These data suggest that the SR-11 sucAB is prob-
ably avirulent due to the unavailability of one of the supple-
ments in vivo, most likely diaminopimelate, which is required
for succinyl-CoA synthesis. Finally, the SR-11 ppc mutant is
unable to convert PEP to oxaloacetate and, therefore, does not
grow on glucose aerobically unless cofactor amounts (0.01%)
of both aspartate and -ketoglutarate are added to the me-
dium (47). Surprisingly, when the SR-11 ppc mutant was
grown in the presence of the supplements, its generation time
was still 44% greater than the wild-type SR-11 (P  0.001)
(Table 4), yet it was fully virulent in BALB/c mice (Table 3). It
will be of great interest to determine whether the SR-11 ppc
mutant and the wild-type SR-11 strain grow equally well in
Peyer’s patches and in macrophages in vivo.
The DctA and KgtP transporters are not required for re-
plenishing TCA cycle intermediates during SR-11 infection
(108 CFU/mouse, peroral route). Taken together, the evidence
described above suggests that cyclic operation of the TCA
cycle and formation of pyruvate from malate are important for
full virulence of SR-11 in BALB/c mice. Since gluconeogenesis
is not required for full virulence, it appears that SR-11 can use
sugars for growth in vivo. Yet the SR-11 ppc mutant is fully
virulent despite being unable to replenish the TCA cycle when
grown on sugars as sole carbon and energy sources (47). The
fact that Ppc is not required to replenish TCA intermediates
and that malate appears to be removed from the TCA cycle to
serve as a major source of pyruvate suggests the possibility that
TCA cycle intermediates can be replenished during infection
independently of Ppc. Therefore, we wanted to test whether
uptake of TCA cycle intermediates was important for SR-11
virulence. DctA is a sodium-dependent dicarboxylate trans-
porter, responsible for the uptake of fumarate, succinate, and
malate under aerobic conditions as well as for the uptake of
orotate, a pyrimidine precusor (10). KgtP is a proton-driven
transporter for -ketoglutarate, which is constitutively ex-
pressed (45). SR-11 kgtP, SR-11 dctA, and SR-11 kgtP
dctA mutants were constructed, and each strain was tested for
virulence. The SR-11 kgtP mutant (P  0.26), the SR-11
dctA mutant (P  0.71), and the SR-11 kgtP dctA double
FIG. 5. Survival of BALB/c mice infected orally with 108 CFU of
either wild-type SR-11 (■) or the SR-11 sfcA maeB double mutant
(E).
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mutant (P  0.98) were each fully virulent (Table 3). There-
fore, although we have not as yet identified the intermediates
that replenish the TCA cycle, it appears that neither DctA nor
KgtP is required for uptake of TCA cycle intermediates during
SR-11 infection of BALB/c mice. Note that neither the anaer-
obic systems for dicarboxylate uptake (16, 34) nor the citrate
transport system (52) were tested.
Virulence of SR-11 mutants via the intraperitoneal route
(103 CFU/mouse). Since SR-11 growth presumably takes place
in lymphoid cells of the Peyer’s patches (20, 22) and in mac-
rophages in the liver and spleen when mice are infected via the
peroral route (24, 40), the SR-11 mutants that were at least
moderately attenuated (SR-11 mdh, SR-11 sfcA maeB,
SR-11 sdhCDA, and SR-11 sucCD) or avirulent perorally
(SR-11 sucAB) were tested for virulence via the intraperito-
neal (i.p.) route. The SR-11 sucAB mutant, which was avir-
ulent via the oral route was also avirulent i.p. (P  0.0001)
(Fig. 6A). The SR-11 sfcA maeB mutant (P  0.0011), the
SR-11 sdhCDA mutant (P  0.0014), and the SR-11 sucCD
mutant (P  0.0003) were attenuated i.p. to about the same
extent as via the peroral route (Fig. 6B to D); however, the
SR-11 mdh mutant (P  0.0014) appeared to be less atten-
uated via the i.p. route than perorally (compare Fig. 4C and
6E), suggesting that sources of replenishment of oxaloacetate
for SR-11 during growth in macrophages in the liver and
spleen may be more plentiful than for growth of SR-11 in the
Peyer’s patches.
DISCUSSION
While the virulence mechanisms of serovar Typhimurium
have been studied intensively, little is known about the central
FIG. 6. Survival of BALB/c mice infected intraperitoneally with 103 CFU of either wild-type SR-11 (■) or the SR-11 sucAB mutant (E) (A),
103 CFU of either wild-type SR-11 (■) or the SR-11 sfcA maeB double mutant (E) (B), 103 CFU of either wild-type SR-11 (■) or the SR-11
sdhCDA mutant (E) (C), 103 CFU of either wild-type SR-11 (■) or the SR-11 sucCD mutant (E) (D), or 103 CFU of either wild-type SR-11
(■) or the SR-11 mdh mutant (E) (E).
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metabolic pathways used during infection. As a first step, we
used systematic mutational analysis to evaluate the involve-
ment of central metabolic pathways in SR-11 virulence in
BALB/c mice. While we believe that this approach has merit,
there are several reasons that the data must be interpreted with
caution. First, the fact that a specific mutation has no effect on
virulence does not rule out the possibility that the disrupted
metabolic pathway normally plays a role in virulence, i.e., it is
possible that an alternative pathway can compensate for the
defect. Second, it is possible that virulence gene expression
may be regulated by specific metabolic signals, and thus, while
attenuation of a specific mutant might be attributed to inter-
ruption of a metabolic pathway, attenuation might be primarily
caused by repression of virulence factor synthesis. Third, vir-
ulence is a highly complicated process involving many different
types of host-bacterium interactions, any one of which could be
affected by a specific metabolic defect. Thus, a specific meta-
bolic defect might have important consequences at one stage
of infection but not at another stage. The virulence assay em-
ployed here cannot address this possibility. Fourth, we have
not complemented each of the attenuated and avirulent mu-
tants with the wild-type gene or genes that each is missing to be
sure that full virulence has been restored. Nevertheless, de-
spite these caveats, and recognizing that far more work will be
required to fully understand serovar Typhimurium central me-
tabolism in vivo, including studies of central carbon metabo-
lism in Peyer’s patches and in macrophages in vivo, we offer the
following possibilities to explain our data.
Gluconeogenesis (fbp glpX mutant and ppsA pckA mu-
tant) and the anapleurotic replenishment of oxaloacetate in
the TCA cycle from PEP (ppc mutant) appear not to be
needed for full SR-11 virulence, but formation of pyruvate
from malate, which would require replenishment of TCA cycle
intermediates, does appear to be important (sfcA maeB
mutant). It is also clear that cyclic operation of the TCA cycle
(sucAB, sucCD, sdhCDA mutants) is important for full
virulence. Thus, the data are consistent with the hypothesis
that during infection of BALB/c mice, SR-11 grows in a mixed
mode using glycolytic sugars and either amino acids or inter-
mediates of the TCA cycle to replenish the TCA cycle, thereby
allowing formation of pyruvate from malate.
Apparently, the majority of PEP required for full SR-11
virulence can be generated by glycolysis, i.e., blocking PEP
production via the gluconeogenic pathway did not have a ma-
jor effect on virulence (Fig. 2). Furthermore, as stated above,
the fact that the SR-11 ppc mutant is fully virulent (Fig. 3)
suggests that replenishment of oxaloacetate from PEP is not
required. Three nonexclusive interpretations of these results
are possible. First, the PEP generated by glycolysis is con-
sumed in other ways, e.g., during transport of sugars by the
PTS system, during synthesis of vitamins and cofactors, and
perhaps during synthesis of the aromatic amino acids, etc., and
is therefore not available to replenish oxaloacetate. Second,
sugar concentrations are insufficient to produce enough PEP to
drive cyclic operation of the TCA cycle. Third, uptake of TCA
cycle intermediates or substrates that feed into the TCA cycle
obviate the need for the anapleurotic reaction catalyzed by
Ppc.
We have not as yet identified anapleurotic reactions that
replenish the TCA cycle. However, since the SR-11 dctA
kgtP double mutant is fully virulent (Table 4), it appears that
SR-11 does not transport extracellular -ketoglutarate, fuma-
rate, succinate, and malate aerobically for this purpose. It is
still possible, however, that SR-11 transports dicarboxylates
anaerobically during infection, since serovar Typhimurium
contains genes for anaerobic dicarboxylate transport (16, 34)
that were not tested here. It is also possible that other untested
anapleurotic reactions contribute to replenishing TCA cycle
intermediates. For example, serovar Typhimurium can take up
extracellular citrate via the TctABC transporter (52), which
could enter directly into the TCA cycle or be converted to
oxaloacetate via a putative citrate lyase (28).
Although a complete TCA cycle appears to be required for
full SR-11 virulence, deleting different TCA cycle genes re-
sulted in different levels of attenuation. Thus, the SR-11
sucAB mutant is avirulent (Fig. 4A), the SR-11 mdh mutant
is highly attenuated (Fig. 4C), the SR-11 sfcA maeB mutant
and the SR-11 sucCD mutants are moderately attenuated
(Fig. 4B and 5), and the SR-11 sdhCDA mutant is least
attenuated (Fig. 4E). One explanation as to why the SR-11
sdhCDA mutant is less attenuated than the other TCA cycle
attenuated mutants is the possibility that endogenous fumarate
reductase present in SR-11 cells may be able to substitute for
succinate dehydrogenase (6, 19) and thereby lessen the effect
of the sdhCDA mutation. It will therefore be of interest to
test the virulence of an SR-11 frdABCD sdhCDA double
mutant. In contrast, the SR-11 sucAB mutant is presumably
avirulent because the strain is unable to make succinyl-CoA
during infection. Succinyl-CoA is required for biosynthesis of
diaminopimelate, a precursor for the synthesis of lysine, me-
thionine, and peptidoglycan (4, 5, 15, 17, 30).
Although the data presented here implicate the utilization of
sugars for full SR-11 virulence, at the present time we don’t
know which sugars are metabolized during SR-11 infection,
although it has recently been suggested that serovar Typhi-
murium utilizes gluconate, a non-PTS sugar, for growth in
macrophages in vitro (12). PTS sugars all utilize PtsI, which is
phosphorylated by PEP (38). Recently, a serovar Typhimurium
ptsI mutant was shown to be attenuated via the i.p. route (23);
however, ptsI mutants are not only unable to transport PTS
sugars, they are unable to utilize a number of non-PTS sugars
and TCA cycle intermediates for growth (38). Therefore, to
identify sugars that contribute to virulence, it will be necessary
to knock out the ability to utilize individual sugars and test
their virulence.
Serovar Typhimurium grows both in lymphoid cells and
macrophages in the Peyer’s patches and in macrophages after
it crosses the intestine and disseminates systemically (22, 24,
40, 43). Therefore, the data obtained from infection via the
oral route presumably reflect a composite of growth in lym-
phoid cells and macrophages, whereas the data obtained by
infection via the i.p. route probably reflect growth in macro-
phages. In general, those mutants that were either avirulent or
attenuated via the oral route remained as such via the i.p.
route; however, the SR-11 mdh mutant was clearly more
attenuated orally than i.p. (compare Fig. 4C and 6E). It will be
of great interest to determine the growth rates of the wild-type
SR-11 and the attenuated SR-11 mutants in Peyer’s patches
and in macrophages in vivo.
Finally, it is clear that the inability to perform gluconeogen-
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esis is not the reason the SR-11 cra mutant is avirulent. Cra
is thought to bind to DNA and exert its regulatory effects only
when growth takes place on gluconeogenic substrates, i.e., not
in the presence of sugars as carbon sources (42). Yet the data
presented here suggest that SR-11 utilizes sugars for growth in
vivo. However, if in vivo SR-11 grows on low levels of sugars,
Cra could still play a role during infection. Fructose-1,6-
bisphosphate is the effector that removes Cra from its target
promoters when growth takes place in the presence of high
sugar levels (42). Low levels of sugars would presumably not
generate a high enough concentration of fructose-1,6-bisphos-
phate to remove Cra from its target promoters. As a conse-
quence, despite sugars being used for SR-11 growth in vivo,
Cra could still positively regulate both the TCA cycle and
electron transport systems (42) and perhaps serve to positively
regulate virulence gene expression, along with other known
regulators (25). Further research is required to examine these
possibilities.
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